News

The two-year collaboration is being led by Dan S. Kaufman, M.D., Ph.D., Professor of Medicine in the Division of Regenerative Medicine and Director of Cell Therapy at UC

As part of the agreement, Carmot will apply its proprietary lead-identification technology, Chemotype Evolution, to discover and advance novel drug leads intended for the treatment of Parkinson’s disease

The trial, dubbed MONALEESA-7, saw Kisqali, a CDK4/6 inhibitor, combined with an aromatase inhibitor or tamoxifen and goserelin as initial endocrine-based therapy pitted against endocrine therapy and goserelin alone.

Janssen Biotech, along with AbbVie’s Pharmacyclics, has developed Imbruvica, which is a first-in-class Bruton's tyrosine kinase inhibitor. iNNOVATE is a Pharmacyclics-sponsored, randomized, placebo-controlled and double-blind study designed to

C-Bridge Capital has invested $50 million to fund Everest and has assembled a veteran leadership team with an established track record in both the development of innovative drugs

The trial is being conducted in the United States and top line data is expected in Q3 2018. The Phase 2 study is a randomized, double-blind, vehicle-controlled, multicenter,

The FDA has approved the once-weekly analogue of human glucagon-like peptide-1 (GLP-1) receptor agonist in 0.5mg and 1mg therapeutic dosages with the injection indicated to be used as

University of Queensland scientists are hoping clinical trials could soon be underway for people with lung, pancreatic and colorectal cancers that have not responded to other therapies. UQ

Under the terms of the agreement, PsychoGenics is providing access to its powerful phenotypic discovery platforms, including its SmartCube system and machine learning expertise, for unbiased discovery of